Wilmington Savings Fund Society FSB Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Wilmington Savings Fund Society FSB grew its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,559 shares of the medical equipment provider’s stock after buying an additional 363 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Zimmer Biomet were worth $693,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet in the third quarter worth approximately $28,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet in the third quarter worth $35,000. R Squared Ltd purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at $63,000. Finally, Mather Group LLC. boosted its holdings in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 332 shares during the period. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Oppenheimer decreased their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday. Finally, Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $100.40 on Tuesday. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $99.67 and a 12 month high of $133.90. The company has a market capitalization of $19.99 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.83 and a beta of 1.02. The firm’s 50-day moving average is $107.34 and its 200 day moving average is $108.07.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business earned $2.20 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.